www.StockMarketingInc.com: Hot Stock Alert!! UNDT - Universal Detection Technology to Present Hand-Held Bioterrorism Detection for 2012 London Olympics at the Terrorism & Security 2009 Conference, Endorsed by ACPO TAM and NYPD Intelligence Division :: Our Newsletter is On Fire!!

STOCK MARKETING INC PRESENTS :

(OTCBB: UNDT - Universal Detection Technology) (NASDAQ: LTON - Linktone Ltd.) (NASDAQ: LXRX - Lexicon Pharmaceuticals, Inc.) (NASDAQ: NVAX - Novavax, Inc.)

www.StockMarketingInc.com

To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com

email us!! info@StockMarketingInc.com or call 1-866-583-8960

---------------------------------------------------------------------------------------------------------------------------------------------- --------------

OTCBB: UNDT - Universal Detection Technology)

LATEST NEWS!!

UNDT - Universal Detection Technology

Universal Detection Technology to Present Hand-Held Bioterrorism Detection for 2012 London Olympics at the Terrorism & Security 2009 Conference, Endorsed by ACPO TAM and NYPD Intelligence Division 2012 London Olympics Organizers and Senior Personnel in Government and Commercial Sectors to Address Growing Threat of Bio-Weapons, Review Counter-Terrorism Strategies

LOS ANGELES, CA, Oct 21, 2009 -- Universal Detection Technology (www.udetection.com) (OTCBB: UNDT), a developer of early-warning monitoring technologies and counter-terrorism training programs to protect people from bioterrorism and other infectious health threats, announced today that it will present its rapid response biodetection kits to the 2012 London Olympics organizers at the 2009 Terrorism & Security Conference, held in London on November 17th and 18th.

"The security risks associated with high-profile international events, such as the 2012 London Olympics, cannot be underestimated," said Jacques Tizabi, CEO of Universal Detection Technology. "Bio-weapons should be a particular concern to organizers, because for terrorists, they can be purchased or engineered at relatively low costs, can induce mass casualties and are oftentimes undetected by on-the-ground law enforcement; Universal Detection Technology is prepared to meet the bioterrorism detection needs of the 2012 London Olympics and similar global venues," continued Tizabi.

UNDT was invited by the conference to present to the 2012 London Olympics organizers and security directors of international "high-value, soft -targets," including airports, sports stadiums, national infrastructure, shopping centers, prestigious hotels and mass transport hubs to and from the United Kingdom and Europe.

Following the 2009 Terrorism & Security Conference in London, Universal Detection Technology will also be presenting its bioterrorism detection equipment at the upcoming 2009 Milipol Conference in Paris, November 17-20.

Universal Detection Technology's 5-agent biodetection kits, recently certified by United States Department of Homeland Security as an "Approved Product for Homeland Security" under the Support Anti-terrorism by Fostering Effective Technologies (SAFETY) Act of 2002, are the industry's only hand-held assay designed to detect and identify up to five separate threats using one sample in a single, easy-to-use device. The kits equip first responders with an effective tool for the rapid onsite detection of up to five biological warfare agents: anthrax, ricin, botulinum toxin, Y. pestis (plague) and Staphylococcal Enterotoxin B (SEB). Detection time is under three minutes.

For more information, please visit www.udetection.com or email info@udetection.com.

About Universal Detection Technology

Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, Universal Detection Technology, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems and antimicrobial products.

www.udetection.com.

Forward-Looking Statements

Except for historical information contained herein, the statements in this news release are forward-looking statements that involve known and unknown risks and uncertainties, which may cause the Company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations. ---------------------------------------------------------------------------------------------------------------------------------------------- --------------

(NASDAQ: LTON - Linktone Ltd.)

LATEST NEWS!!

Linktone Announces Results of 2009 Annual General Meeting of Shareholders

BEIJING, Oct 20, 2009 -- Linktone Ltd. (Nasdaq: LTON) (the "Company"), one of the leading providers of wireless interactive entertainment products and services to consumers in China, today announced the results of its 2009 Annual General Meeting of Shareholders held on October 19, 2009, at 10:00 a.m., Beijing time, at its offices located at 27/F, Building 1, Landmark Towers, 8 North East Third Ring Road, Chao Yang District, Beijing 100004, People's Republic of China.

The Company's shareholders approved all proposals set forth in the proxy statement dated September 23, 2009. The approved proposals were:

-- Elect Oerianto Guyandi as a Class II director to serve until the 2012 annual general meeting of shareholders or until his successor is elected and duly qualified.

-- Ratify the appointment of Ernst & Young Hua Ming as independent registered public accountants of Linktone Ltd. for the fiscal year ending December 31, 2009.

-- Approve AS A SPECIAL RESOLUTION an amendment to the Company's Amended and Restated Memorandum and Articles of Association to (i) remove the existing requirement that material transactions between the Company and any holder of 5% or more of the Company's share capital or any affiliate of the Company be approved (x) by a majority of the disinterested directors of the Company's board, in the case of transactions valued at or above US$1 million, and (y) by holders of a majority of the shares held by the Company's disinterested shareholders, in the case of transactions valued at or above US$10 million, and (ii) replace with the requirement that transactions between the Company and any holder of 5% or more of the Company's share capital or any affiliate of the Company be approved by a majority of the disinterested directors of the Company's board, in the case of transactions valued at or above US$5 million.

About Linktone Ltd.

Linktone Ltd. is one of the leading providers of wireless interactive entertainment services to consumers in China. Linktone provides a diverse portfolio of services to wireless consumers and corporate customers, with a particular focus on media, entertainment and communications. These services are promoted through the Company's strong distribution network, integrated service platform and multiple marketing sales channels, as well as through the networks of the mobile operators in China. Through in-house development and alliances with international and local branded content partners, the Company develops, aggregates, and distributes innovative and engaging products to maximize the breadth, quality and diversity of its offerings.

---------------------------------------------------------------------------------------------------------------------------------------------- --------------

(NASDAQ: LXRX - Lexicon Pharmaceuticals, Inc.)

LATEST NEWS!!

Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2009 Financial Results on October 27, 2009

--Conference Call and Webcast to Follow

THE WOODLANDS, Texas, Oct 20, 2009 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2009 financial results on Tuesday, October 27, 2009 before the financial markets open. Lexicon management will hold a conference call to discuss its clinical development progress and financial results for third quarter 2009 at 11:00 a.m. Eastern Time on October 27, 2009.

The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international). The conference ID for all callers is 36026166. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website through November 3, 2009.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.

---------------------------------------------------------------------------------------------------------------------------------------------- --------------

(NASDAQ: NVAX - Novavax, Inc.)

LATEST NEWS!!

Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico

---- Pivotal Clinical Study to Evaluate H1N1 VLP Vaccine Safety, Immunogenicity and Efficacy in Mexico---- Novavax forms Alliance with Avimex

Laboratories to support the Clinical Trial and Potential Commercial Distribution of the H1N1 vaccine in Mexico---- GE Healthcare Provides

Support with its Novel Disposable Bioprocessing Technologies

ROCKVILLE, Md., Oct 20, 2009 -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has initiated a two-stage clinical study of its virus- like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare. Avimex distributes biological and pharmaceutical products for use in Mexico and more than 25 other countries around the world. Avimex is providing financial support for the trial and is expected to distribute the H1N1 VLP vaccine in Mexico in 2010 if it is approved for commercial sale. In addition, Novavax also announced today that GE Healthcare (a unit of General Electric Company (NYSE: GE)) has agreed to support this program by providing its single-use bioprocessing technologies for vaccine production. GE Healthcare and Novavax have worked together since December 2007 to develop innovative vaccine production solutions using GE Healthcare's manufacturing technologies.

"This clinical study represents a unique opportunity to accelerate the development of our pandemic 2009 H1N1 flu VLP vaccine and address an important public health problem in Mexico. Conducting this clinical trial during a pandemic, when the attack rate of the H1N1 virus is expected to be very high, provides the company with an invaluable opportunity to demonstrate field efficacy of its VLP-based H1N1 vaccine and the utility of the VLP vaccine platform for influenza as a whole," said Dr. Rahul Singhvi, President and CEO of Novavax. "Our new alliance with Avimex is another example of our regional strategy and will provide valuable assistance toward the successful completion of this important clinical study within a remarkably short horizon. The fast spread of H1N1 worldwide has caused a significant strain on vaccine supply in countries with limited indigenous vaccine capabilities. We are grateful to the Mexican health authorities for their rapid clinical protocol clearance and enabling our potential solution for this escalating unmet medical need," Dr. Singhvi added. "We are delighted to support Novavax as they move into this exciting clinical trial," said Catarina Flyborg, Enterprise Solutions Leader, GE Healthcare. "Alongside growing interest from organizations in India and Spain, this trial lends further credence to the combination ofNovavax's vaccine technology with GE Healthcare's ReadyToProcess bioprocessing solutions."

Novavax and Avimex are initiating the blinded, placebo-controlled clinical trial in Mexico City to evaluate the safety, immunogenicity and efficacy of Novavax's 2009 H1N1 VLP vaccine in healthy adults. The first stage will evaluate the vaccine's safety, immunogenicity and efficacyamong 1,000 subjects, including 750 VLP recipients and 250 placebo recipients. Pending favorable results from the first stage, the second stage of the study will be initiated to evaluate the safety of the vaccine in a larger cohort of 3,000 subjects (2,000 vaccine and 1,000 placebo recipients). The primary safety and immunogenicity results are expected within 3 months of the start of this study in January 2010. If the results are clinically acceptable, they will be used to seek registration of Novavax's 2009 H1N1 pandemic flu vaccine in Mexico. These data are also expected to support development of the company's pandemic and seasonal flu VLP vaccines in other countries, including the United States.

"We are pleased to be working with GE Healthcare, Avimex and the leading health officials in Mexico to launch the first and largest clinical trial to date using the 2009 H1N1 influenza VLP-based vaccine," said Thomas Johnston, Vice President of Strategy at Novavax. "This study is a continuation of our efforts to respond quickly to this current pandemic by leveraging our proprietary recombinant VLP technology and our innovative manufacturing solution. We appreciate having the opportunity and support to demonstrate the H1N1 vaccine's safety, immunogenicity and efficacy in Mexico and thereby help with ongoing pandemic response efforts. Similar to our previous announcements regarding our ongoing work in the countries of India and Spain, where we plan to establish in-border production, our planned clinical work in Mexico, if successful, could lead to rapid availability of the vaccine and advance Novavax's regional strategy to assist countries around the globe with such critical needs."

Virus-like particles (VLPs) mimic the external structure of viruses but lack the live genetic material that causes viral replication and infection. VLPs can be designed quickly to match individual viral strains and be produced efficiently using portable cell-culture technology.

Novavax's VLP-based vaccine candidates are produced significantly more quickly than egg-based vaccines by using proprietary, portable, recombinant cell-culture technology.

The company will hold an investor conference call to discuss this clinical study at 9:00 a.m. Eastern Time on Tuesday, October 20, 2009. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of the company's senior management team. A question and answer session will follow. The dial-in number for the conference call is 1 (866) 206-5917 (International: 1 (703) 639-1106). A live audio webcast of the conference call will be available at www.novavax.com under Investors/Events. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast.

A replay of the webcast will be available on the website for 90 days after the call and a replay of the conference call will also be available by telephone beginning October 20, 2009 at 1:00 p.m. Eastern Time through October 22, 2009 at 11:59 p.m. To access the replay, dial 1 (888)266- 2081 and enter pass code 1405084.

About Novavax

Novavax is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP -based, recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. It recently launched a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.

Forward-Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical trials and development of the 2009 H1N1 vaccine, the potential use of any data from clinical trials and other anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including clinical trial results, which may not be sufficient for regulatory approval or may indicate safety concerns not yet encountered; even if the results of the planned clinical trial are positive, the data may not be accepted by regulatory bodies in other countries or the 2009 H1N1 vaccine may not be approved by the Mexican government or additional clinical trials may be required; if approved, approval of the 2009 H1N1 vaccine may not be timely and thus may not be granted until after the 2009/2010 flu season has ended; sales of the 2009 H1N1 vaccine are not scheduled begin until late in the 2009/2010 flu season which could result in poor sales; Avimex is expected to be responsible for sales of the 2009 H1N1 vaccine in Mexico, thus, the Company would be dependent on Avimex's sales effort; the Company has not yet manufactured, or relied on third parties to manufacture, any vaccines at a commercial scale; the 2009 H1N1 vaccine must be manufactured in a short period of time and will be subject to scale-up, validation and inspection; competition from already approved vaccines for the 2009 H1N1 flu; business abilities and judgment of personnel and corporate partners; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

SOURCE Novavax, Inc.

---------------------------------------------------------------------------------------------------------------------------------------------- --------------

About StockMarketingInc.com

StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

CONTACT: StockMarketingInc.com e-mail: info@StockMarketingInc.com Tel: +1 866 583 8960

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: annual report, anthrax, beijing, biotechnology, business, ceo, china, clinical, commercial, communications, conference, corporate, diabetes, disease, email, e-mail, entertainment, europe, financial results, fire, government, health, healthcare, homeland security, india, infection, investment opinion, joint venture, law enforcement, local, london, manufacturer, manufacturing, marketing, media, medical, mexico, nasa, nasdaq, nyse, olympics, paris, pharmaceuticals, pipeline, president, products, property, research, sales, securities, security, software, spain, sports, technology, terrorism, texas, training, trial, united states, vaccine, weapons, web, wireless